Nec-1 enhances shikonin-induced apoptosis in leukemia cells by inhibition of RIP-1 and ERK1/2

International Journal of Molecular Sciences

Volumn 13, Issue 6, 2012, Pages 7212-7225

  Han, Weidong ^a   Xie, Jiansheng ^b   Fang, Yong ^a   Wang, Zhanggui ^a   Pan, Hongming ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; ERK1 2; Necrostatin 1; Receptor interacting protein 1; Shikonin

Indexed keywords

CASPASE; CASPASE 8; CASPASE 9; GLYCOPROTEIN P; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; NECROSTATIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RECEPTOR INTERACTING PROTEIN 1; SHIKONIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; AGFG1 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 3; NAPHTHOQUINONE; NECROSTATIN-1; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOPORIN; RELA PROTEIN, HUMAN; RNA BINDING PROTEIN;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CELL STRUCTURE; CHILD; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVATION; FEMALE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; NECROPTOSIS; PRESCHOOL CHILD; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; ACTIVE TRANSPORT; ANTAGONISTS AND INHIBITORS; CELL NUCLEUS; DRUG EFFECTS; GENETICS; HL 60 CELL LINE; K562 CELL LINE; LEUKEMIA; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CELL NUCLEUS; HL-60 CELLS; HUMANS; IMIDAZOLES; INDOLES; K562 CELLS; LEUKEMIA; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NAPHTHOQUINONES; NUCLEAR PORE COMPLEX PROTEINS; RNA-BINDING PROTEINS; TRANSCRIPTION FACTOR RELA;

EID: 84862490700     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13067212     Document Type: Article

References (29)

1. Vandenabeele, P.; Galluzzi, L.; Vanden Berghe, T.; Kroemer, G. Molecular mechanisms of necroptosis: An ordered cellular explosion. Nat. Rev. Mol. Cell Biol. 2010, 11, 700-714.
2. Degterev, A.; Huang, Z.; Boyce, M.; Li, Y.; Jagtap, P.; Mizushima, N.; Cuny, G.D.; Mitchison, T.J.; Moskowitz, M.A.; Yuan, J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 2005, 1, 112-119.
3. Degterev, A.; Hitomi, J.; Germscheid, M.; Ch'en, I.L.; Korkina, O.; Teng, X.; Abbott, D.; Cuny, G.D.; Yuan, C.; Wagner, G.; et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 2008, 4, 313-321.
4. Cho, Y.S.; Challa, S.; Moquin, D.; Genga, R.; Ray, T.D.; Guildford, M.; Chan, F.K. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009, 137, 1112-1123.
5. Smith, C.C.; Davidson, S.M.; Lim, S.Y.; Simpkin, J.C.; Hothersall, J.S.; Yellon, D.M. Necrostatin: A potentially novel cardioprotective agent? Cardiovasc. Drugs Ther. 2007, 21, 227-233.
6. Li, Y.; Yang, X.; Ma, C.; Qiao, J.; Zhang, C. Necroptosis contributes to the NMDA-induced excitotoxicity in rat's cultured cortical neurons. Neurosc. Lett. 2008, 447, 120-123.
7. Han, W.; Li, L.; Qiu, S.; Lu, Q.; Pan, Q.; Gu, Y.; Luo, J.; Hu, X. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol. Cancer Ther. 2007, 6, 1641-1649.
8. Ahn, B.Z.; Baik, K.U.; Kweon, G.R.; Lim, K.; Hwang, B.D. Acylshikonin analogues: Synthesis and inhibition of DNA topoisomerase-I. J. Med. Chem. 1995, 38, 1044-1047.
9. C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr. Med. Chem. 2000, 7, 39-58.
10. Kim, S.H.; Kang, I.C.; Yoon, T.J.; Park, Y.M.; Kang, K.S.; Song, G.Y.; Ahn, B.Z. Antitumor activities of a newly synthesized shikonin derivative, 2-hyim-DMNQ-S-33. Cancer Lett. 2001, 172, 171-175.
11. Nakaya, K.; Miyasaka, T. A shikonin derivative, beta-hydroxyisovalerylshikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases. Anticancer Drugs 2003, 14, 683-693.
12. Xuan, Y.; Hu, X. Naturally-occurring shikonin analogues-A class of necroptotic inducers that circumvent cancer drug resistance. Cancer Lett. 2009, 274, 233-242.
13. Yang, H.; Zhou, P.; Huang, H.; Chen, D.; Ma, N.; Cui, Q.C.; Shen, S.; Dong, W.; Zhang, X.; Lian, W.; et al. Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int. J. Cancer 2009, 124, 2450-2459.
14. Chang, I.C.; Huang, Y.J.; Chiang, T.I.; Yeh, C.W.; Hsu, L.S. Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells. Biol. Pharm. Bull. 2010, 33, 816-824.
15. Han, W.; Xie, J.; Li, L.; Liu, Z.; Hu, X. Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis. Apoptosis 2009, 14, 674-686.
16. Festjens, N.; Vanden Berghe, T.; Cornelis, S.; Vandenabeele, P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ. 2007, 14, 400-410.
17. Cho, Y.; McQuade, T.; Zhang, H.; Zhang, J.; Chan, F.K. RIP1-Dependent and independent effects of necrostatin-1 in necrosis and T cell activation. PLoS One 2011, 6, doi:10.1371/journal.pone.0023209.
18. Lin, Y.; Devin, A.; Rodriguez, Y.; Liu, Z.G. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev. 1999, 13, 2514-2526.
19. Vandenabeele, P.; Declercq, W.; van Herreweghe, F.; Vanden Berghe, T. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci. Signal 2010, 3, doi:10.1126/scisignal.3115re4.
20. Galluzzi, L.; Aaronson, S.A.; Abrams, J.; Alnemri, E.S.; Andrews, D.W.; Baehrecke, E.H.; Bazan, N.G.; Blagosklonny, M.V.; Blomgren, K.; Borner, C.; et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 2009, 16, 1093-1107.
21. Balmanno, K.; Cook, S.J. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009, 16, 368-377.
22. Sheridan, C.; Brumatti, G.; Martin, S.J. Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim. J. Biol. Chem. 2008, 283, 22128-22135.
23. Ewings, K.E.; Wiggins, C.M.; Cook, S.J. Bim and the pro-survival Bcl-2 proteins: Opposites attract, ERK repels. Cell Cycle 2007, 6, 2236-2240.
24. Vanlangenakker, N.; Vanden Berghe, T.; Bogaert, P.; Laukens, B.; Zobel, K.; Deshayes, K.; Vucic, D.; Fulda, S.; Vandenabeele, P.; Bertrand, M.J. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ. 2010, 18, 656-665.
25. Bertrand, M.J.; Vandenabeele, P. RIP1's function in NF-kappaB activation: From master actor to onlooker. Cell Death Differ. 2010, 17, 379-380.
26. Ting, A.T.; Pimentel-Muinos, F.X.; Seed, B. RIP mediates tumor necrosis factor receptor 1 activation of NF-κB but not Fas/APO-1-initiated apoptosis. EMBO J. 1996, 15, 6189-6196.
27. Rebe, C.; Cathelin, S.; Launay, S.; Filomenko, R.; Prevotat, L.; L'Ollivier, C.; Gyan, E.; Micheau, O.; Grant, S.; Dubart-Kupperschmitt, A.; et al. Caspase-8 prevents sustained activation of NF-κB in monocytes undergoing macrophagic differentiation. Blood 2007, 109, 1442-1450.
28. Vande Walle, L.; Wirawan, E.; Lamkanfi, M.; Festjens, N.; Verspurten, J.; Saelens, X.; Vanden Berghe, T.; Vandenabeele, P. The mitochondrial serine protease HtrA2/Omi cleaves RIP1 during apoptosis of Ba/F3 cells induced by growth factor withdrawal. Cell Res. 2010, 20, 421-433.
29. Biton, S.; Ashkenazi, A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-α feedforward signaling. Cell 2011, 145, 92-103.